Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Lantern Pharma Inc.

< Previous 1 2 Next >
Lantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma to Report Second Quarter 2023 Operating & Financial Results on August 9, 2023 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma to Participate and Present at Multiple Upcoming Conferences
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgkin’s Lymphomas
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma to Present at the Lytham Partners Spring 2023 Investor Conference Thursday, May 18th at 9:00 a.m. ET
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Reports First Quarter 2023 Financial Results and Operational Highlights
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma to Report First Quarter 2023 Operating & Financial Results on May 9, 2023 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Develops Top-Ranked AI Algorithms to Predict the Blood-Brain-Barrier Permeability of Any Compound
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Receives Notice of Allowance for Composition of Matter Patent Covering Drug Candidate LP-284
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Announces First Patient Dosed in the Phase 2 Study, Harmonic™, for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma to Present at Upcoming Scientific Conferences and Webinars
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational Highlights
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual Meeting
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2022 Operating & Financial Results on March 20, 2023 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Confirms It Had No Exposure to Silicon Valley Bank (SVB), Silvergate Bank, or Signature Bank
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Announces New Data and Development Focus for LP-100 with PARP Inhibitors
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain Cancers
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Expands Clinical Leadership Team to Further Advance its Ongoing and Upcoming Clinical Trials
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug Conjugates
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path for Drug Candidate LP-184’s Phase 1 Clinical Trial in Q2 2023
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in Mantle Cell Lymphoma
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284 for Mantle Cell Lymphoma (MCL) at the American Society of Hematology (ASH) 2022 Annual Meeting
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS)
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-184 for Glioblastoma at the Society for Neuro-Oncology Annual Meeting
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Reports Third Quarter 2022 Financial Results and Operational Highlights
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma Management to Present at Upcoming Investor Conferences in Q4
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
Lantern Pharma to Report Third Quarter 2022 Operating & Financial Results on November 7, 2022 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
Tickers LTRN
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.